Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Placebo, multiple ascending doses, oral suspension
DRUG
2 trials
Sponsors
Galapagos NV
Conditions
Healthy
Phase 1
First-in-Human Single and Multiple Dose of GLPG1205
Completed
NCT01887106
Galapagos NV
Healthy
Start: 2013-06-30
End: 2013-10-31
Updated: 2013-10-16
First-in-Human Single and Multiple Dose of GLPG1690
Completed
NCT02179502
Galapagos NV
Healthy
Start: 2014-06-30
End: 2014-12-31
Updated: 2015-09-22
Related Papers
Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: <i>In Vitro</i> and Phase 1 Studies
Clinical Pharmacology in Drug Development
2021-05-06
9 citations
Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials
The Journal of Clinical Pharmacology
2019-04-23
42 citations